| 11.12 0.3 (2.77%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.25 | 1-year : | 18.54 |
| Resists | First : | 13.91 | Second : | 15.87 |
| Pivot price | 12.63  |
|||
| Supports | First : | 10.75 | Second : | 8.94 |
| MAs | MA(5) : | 11.09 |
MA(20) : | 13.2 |
| MA(100) : | 14.92 |
MA(250) : | 17.79 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 4.6 |
| RSI | RSI(14): 31.8 |
|||
| 52-week | High : | 23.1 | Low : | 10.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OGN ] has closed above bottom band by 24.6%. Bollinger Bands are 182.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.24 - 11.3 | 11.3 - 11.36 |
| Low: | 10.71 - 10.8 | 10.8 - 10.87 |
| Close: | 11 - 11.12 | 11.12 - 11.23 |
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Sun, 20 Apr 2025
Cautious Hold Rating on Organon Amid Updated Financials and Market Conditions - TipRanks
Tue, 15 Apr 2025
Organon expands board with new director from Takeda - Investing.com
Tue, 15 Apr 2025
Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan
Tue, 15 Apr 2025
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Business Wire
Tue, 15 Apr 2025
Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan
Tue, 15 Apr 2025
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 258 (M) |
| Shares Float | 257 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 83.2 (%) |
| Shares Short | 18,360 (K) |
| Shares Short P.Month | 18,450 (K) |
| EPS | 3.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.83 |
| Profit Margin | 13.4 % |
| Operating Margin | 18.7 % |
| Return on Assets (ttm) | 7.3 % |
| Return on Equity (ttm) | 429.8 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 14.42 |
| Sales Per Share | 24.81 |
| EBITDA (p.s.) | 6.82 |
| Qtrly Earnings Growth | -80.7 % |
| Operating Cash Flow | 939 (M) |
| Levered Free Cash Flow | 569 (M) |
| PE Ratio | 3.33 |
| PEG Ratio | 0 |
| Price to Book value | 6.07 |
| Price to Sales | 0.44 |
| Price to Cash Flow | 3.05 |
| Dividend | 0.28 |
| Forward Dividend | 0 |
| Dividend Yield | 2.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|